FDA Warns Against Compounded Moxifloxacin Injections

FDA received case reports of TASS (Toxic Anterior Segment Syndrome) following intraocular administration of compounded drugs using moxifloxacin as a bulk drug substance, as well as reports associated with the intraocular administration of repackaged and/or diluted FDA-approved moxifloxacin drugs.

Dr. David Hussong explains the FDA’s recent alert to health care professionals of risks associated with intraocular use of compounded moxifloxacin.

Learn more about this on the FDA website through the link below:
https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerts-health-care-professionals-risks-associated-intraocular-use-compounded-moxifloxacin